Results 81 to 90 of about 45,597 (259)

HIV Dynamics and Integrase Inhibitors

Antiviral Chemistry and Chemotherapy, 2009
The integrase inhibitor (INI) raltegravir has shown promising results in clinical trials to date, reducing second phase HIV RNA levels by 70% in comparison with standard regimens. These trial results have been limited by the 50 copies/ml detection limit of the HIV RNA assay and have not investigated the effect of an INI regimen on levels of latently ...
openaire   +2 more sources

Integrase, LEDGF/p75 and HIV replication [PDF]

Cellular and Molecular Life Sciences, 2008
HIV integrates a DNA copy of its genome into a host cell chromosome in each replication cycle. The essential DNA cleaving and joining chemistry of integration is known, but there is less understanding of the process as it occurs in a cell, where two complex and dynamic macromolecular entities are joined: the viral pre-integration complex and chromatin.
openaire   +2 more sources

Temporal network analysis of comorbidities among people with HIV in South Carolina

HIV Medicine, EarlyView.
Abstract Introduction People with HIV experience a high rate of comorbidities that can complicate their health outcomes. Understanding the prevalence, interrelationships and temporal development of these comorbidities is crucial for improving health management and quality of life for people with HIV.
Yunqing Ma, Matthew Lohman, Monique J. Brown, Yichen Li, Xiaoming Li, Bankole Olatosi, Jiajia Zhang   +6 more
wiley   +1 more source

Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors

Scientific Reports
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these
Mhairi J. McCormack, Patawee Asamaphan, Ellen C. Hughes, Louis Banda, Stephen Kasenda, Chris Davis, Agnieszka M. Szemiel, Amelia Crampin, Abena S. Amoah, Emma C. Thomson, Antonia Ho, Brian J. Willett   +11 more
doaj   +1 more source

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

PLoS ONE, 2014
To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated ...
Joana Cavaco-Silva, Ana Abecasis, Ana Cláudia Miranda, José Poças, Jorge Narciso, Maria João Águas, Fernando Maltez, Isabel Almeida, Isabel Germano, António Diniz, Maria de Fátima Gonçalves, Perpétua Gomes, Celso Cunha, Ricardo Jorge Camacho, Portuguese HIV-2 Resistance Study Group   +14 more
doaj   +1 more source

Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons. [PDF]

, 2017
Objective The contribution of hepatitis C virus (HCV) infection to the risk of heart failure in human immunodeficiency virus (HIV)-coinfected persons is unknown.
Ambale-Venkatesh, Bharath, Bluemke, David A, Butt, Adeel A, Chew, Kara W, Currier, Judith S, Horwich, Tamara B, Liao, Diana, Lima, João AC, Liu, Chia-Ying, Paul Finn, J   +9 more
core   +2 more sources

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, EarlyView.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source

Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection

Nature Communications, 2019
Long-acting formulation of the integrase inhibitor cabotegravir (CAB LA) is in clinical development for HIV pre-exposure prophylaxis (PrEP). Here, using a SHIV macaque model, the authors show emergence of integrase mutations associated to CAB LA PrEP ...
Jessica Radzio-Basu, Olivia Council, Mian-er Cong, Susan Ruone, Alicia Newton, Xierong Wei, James Mitchell, Shanon Ellis, Christos J. Petropoulos, Wei Huang, William Spreen, Walid Heneine, J. Gerardo García-Lerma   +12 more
doaj   +1 more source

Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant

Molecular Therapy: Nucleic Acids, 2014
HIV-1 derived vectors are among the most efficient for gene transduction in mammalian tissues. As the parent virus, they carry out vector genome insertion into the host cell chromatin.
Muhammad Qamar Saeed, Noelle Dufour, Cynthia Bartholmae, Urzula Sieranska, Malaika Knopf, Eloïse Thierry, Sylvain Thierry, Olivier Delelis, Nicolas Grandchamp, Héloïse Pilet, Philippe Ravassard, Julie Massonneau, Françoise Pflumio, Christof von Kalle, François Lachapelle, Alexis-Pierre Bemelmans, Manfred Schmidt, Ché Serguera   +17 more
doaj   +1 more source

Late diagnosis of paediatric HIV infection in high‐income countries: Lessons from the HIV Perinatal Virtual Clinic

HIV Medicine, EarlyView.
Abstract Introduction Timely diagnosis of HIV in children remains a challenge in all settings including low‐prevalence, high‐income countries (HIC). We aimed to characterize the prevalence of late diagnosis, and prior missed diagnostic opportunities among new presentations of paediatric HIV in HIC referred to an international Perinatal Virtual Clinic ...
Carolina Curto, M. Tritzali, A. Bamford, A. C. Bailey, E. G. H. Lyall, N. E. Mackie, N. Tickner, C. Foster, on behalf of the PVC   +8 more
wiley   +1 more source